Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

Macrophage Pharma Ltd.. (6/1/21). "Press Release: Macrophage Pharma Appoints Dr Venkat Reddy as Chief Executive Officer". Windsor.

Organisations Organisation Macrophage Pharma Ltd. (MPL)
  Organisation 2 Glenmark Pharmaceuticals S.A. (GPSA)
Products Product ESM™ technology (Esterase Sensitive Motif technology)
  Product 2 small-molecule drug
Persons Person Reddy, Venkat (Macrophage Pharma 202106– CEO joined 1/20 as CSO before Glenmark Pharma + Pfizer + Sanofi + Novartis)
  Person 2 Rangarajah, Elakiya (Optimum Strategic Communciations 202104)
     


Executive leadership and strategic focus strengthened for sustained company development


Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and early stage development of highly novel small molecule therapeutics with the potential to transform outcome in inflammation, autoimmune disease and cancer through regulation of innate immune response, announced today that its Chief Scientific Officer (CSO), Dr Venkat Reddy PhD, has been appointed by the Board as Chief Executive Officer (CEO).

Commenting on the appointment, Dr Michael Moore, Chairman of Macrophage Pharma, said: “The Board is delighted to have promoted Venkat to CEO. Since joining the Company, Venkat’s influence in combining a strategic biology focus on targets critical for regulated cell death in immune-mediated diseases with the Company’s drug discovery platform based on proprietary Esterase Sensitive Motif™ (ESM™) technology, has been transformative, enhancing the opportunity for commercialisation of our novel small molecule assets for a variety of protein targets and therapeutically unmet diseases.”

Dr Venkat Reddy, CEO of Macrophage Pharma, commented: “I am honoured to have been appointed CEO of Macrophage Pharma. The potential of our ESM™ technology platform to generate novel drugs is compelling as demonstrated by its ability to impact adaptive immunity through selective modulation of myeloid derived innate immune cells. I look forward to continuing my work with Macrophage Pharma’s executive team and Board of Directors to unlock the full therapeutic and commercial potential of the technology across a spectrum of human diseases.”

Venkat Reddy has a successful track record and extensive strategic and management experience from senior executive roles in both European and US biotech and pharma, including Glenmark Pharmaceuticals (SVP, Global Head of Translational Sciences), Pfizer (Senior Director, Strategic Alliances and Partnerships, Centers for Therapeutic Innovation), Sanofi (Senior Director, Head, Bio-Innovation France: Global Biotherapeutics) and Novartis (Group leader, GNF). Venkat holds a PhD from the Ludwig-Maximilians Universität München and undertook post-doctoral studies in immunology and oncology at the Scripps Research Institute. He has served Macrophage Pharma as Chief Scientific Officer since January 2020.


Contacts:

Macrophage Pharma Limited
Dr Venkat Reddy, Chief Executive Officer
Email: venkat@macrophagepharma.com
Tel: +41 78 749 57 57

Optimum Strategic Communications
Hollie Vile, Mary ClarkElakiya Rangarajah
Email: macrophage@optimumcomms.com
Tel: +44 (0) 020 3922 0900

   
Record changed: 2021-06-05

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Macrophage Pharma Ltd. (MPL)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px




» top